Strong PD-L1 Affect Clinical Outcomes in Advanced NSCLC Treated with Third-generation EGFR-TKIs

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Aug 19

PMID 39155845

Authors

Jiling Niu

Xuquan Jing

Qinhao Xu

Haoyu Liu

Yaru Tian

Zhengqiang Yang

Hui Zhu

Yulan Sun

Affiliations

Soon will be listed here.

Abstract

In first/second generation EGFR-TKIs, strong PD-L1 expression contributes to primary resistance, significantly affecting patient prognosis. The relationship between PD-L1 expression levels and third-generation TKIs remains unclear. This study analyzed advanced NSCLC who received third-generation EGFR-TKIs as first-line systemic therapy from March 2019 to June 2022. The EGFR and PD-L1 status of the patients was also assessed. Overall, 150 patients were included in this study. PD-L1 expression was negative (PD-L1 tumor proportion score <1%) in 89 cases, weak (1-49%) in 42 cases, and strong (≥50%) in 19 cases. mPFS for patients with negative, weak and strong PD-L1 expressions was 23.60, 26.12 and 16.60 months, respectively. The mPFS for strong PD-L1 expression was significantly shorter than that for with weak PD-L1 expression but was not associated with negativity. The same conclusions were shown in subgroup analyses of mutation types and TKI kinds. In addition, Relative to PD-L1-negative patients, resistance to TKIs may be associated with early progression for patients with strong PD-L1 expression. PD-L1 expression in tumor cells influenced the clinical outcomes of patients with advanced NSCLC treated with third-generation EGFR-TKIs. Stronger PD-L1 expression in TKIs-treated patients with advanced first-line EGFR-mutated NSCLC was associated with worse PFS.

References

Hsu K, Tseng J, Yang T, Chen K, Su K, Yu S . PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep. 2022; 12(1):9753. PMC: 9192769. DOI: 10.1038/s41598-022-13102-7. View

Su S, Dong Z, Xie Z, Yan L, Li Y, Su J . Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. J Thorac Oncol. 2018; 13(11):1668-1675. DOI: 10.1016/j.jtho.2018.07.016. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

Liu J, Itchins M, Nagrial A, Cooper W, De Silva M, Barnet M . Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2021; 155:28-33. DOI: 10.1016/j.lungcan.2021.03.004. View

Fujiwara Y, Kato S, Nesline M, Conroy J, DePietro P, Pabla S . Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022; 110:102461. DOI: 10.1016/j.ctrv.2022.102461. View

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T . Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014; 25(10):1935-1940. DOI: 10.1093/annonc/mdu242. View

Ohaegbulam K, Assal A, Lazar-Molnar E, Yao Y, Zang X . Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2014; 21(1):24-33. PMC: 4282825. DOI: 10.1016/j.molmed.2014.10.009. View

Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K . EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019; 18(1):165. PMC: 6864970. DOI: 10.1186/s12943-019-1073-4. View

10.

Schabath M, Cote M . Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1563-1579. PMC: 6777859. DOI: 10.1158/1055-9965.EPI-19-0221. View

11.

Trujillo J, Luke J, Zha Y, Segal J, Ritterhouse L, Spranger S . Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019; 7(1):295. PMC: 6839232. DOI: 10.1186/s40425-019-0780-0. View

12.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

13.

Lasvergnas J, Fallet V, Duchemann B, Jouveshomme S, Cadranel J, Chouaid C . PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors. Respir Med Res. 2023; 84:101018. DOI: 10.1016/j.resmer.2023.101018. View

14.

Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

15.

Such L, Zhao F, Liu D, Thier B, Le-Trilling V, Sucker A . Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest. 2020; 130(8):4266-4281. PMC: 7410049. DOI: 10.1172/JCI131572. View

16.

Batra U, Sharma M, Nathany S, Bansal A, Pasricha S, Jain P . EGFR and PDL1: A Match (Not) Made in Heaven-A Real-World Retrospective Analysis of PDL1 Expression in EGFR-Mutated NSCLC. Adv Ther. 2021; 38(4):1791-1800. DOI: 10.1007/s12325-021-01655-4. View

17.

Hack S, Zhu A, Wang Y . Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol. 2020; 11:598877. PMC: 7674951. DOI: 10.3389/fimmu.2020.598877. View

18.

Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N . Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res. 2021; 10(8):3582-3593. PMC: 8435385. DOI: 10.21037/tlcr-21-461. View

19.

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

20.

Wu Y, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. View